Detailed Coverage

Shivalik Rasayan to Raise ₹33 Crore Via Preferential Issue

Shivalik Rasayan will raise ₹33 crore through a preferential issue of 3,72,000 equity shares and 9,48,000 warrants.

Reader Takeaway: Promoter commitment is positive, but dilution is a watch point for existing shareholders.

What just happened

The Board of Directors of Shivalik Rasayan has approved a fundraising plan totaling ₹33 crore. This capital raise will be executed through a preferential issue, which includes the issuance of 3,72,000 equity shares at ₹250 per share, amounting to ₹9.30 crore. Additionally, the company will issue 9,48,000 fully convertible warrants, also priced at ₹250 per warrant, bringing in ₹23.70 crore.

Why this matters

This capital infusion will provide Shivalik Rasayan with additional funds, which can be used for business expansion, working capital, or other strategic initiatives. The issuance of warrants, convertible into equity within 18 months, offers flexibility in capital management. Promoter participation signals confidence in the company's future growth prospects.

The backstory

Shivalik Rasayan Limited is engaged in the business of manufacturing and exporting pharmaceutical formulations and intermediates. The company has previously undertaken capital raising activities to fund its growth.

What changes now

The company has formed a Preferential Issue Committee to finalize the necessary documentation for this fundraising exercise. The crucial next step is obtaining shareholder approval at the Extraordinary General Meeting (EGM) scheduled for August 20, 2026.

Risks to watch

A key concern for existing shareholders is the potential dilution of their ownership stake. The issuance of new equity shares and the future conversion of warrants will increase the total outstanding share capital. Investors need to monitor how this impacts their percentage of ownership and earnings per share.

Promoter Commitment

Indicating strong confidence in the company's future, Growel Remedies Limited, the promoter, will subscribe to 4,28,000 warrants as part of this preferential issue. This commitment from the promoter is a positive signal to the market.

What to track next

Investors should closely watch the outcome of the EGM on August 20, 2026, to confirm shareholder approval for the preferential issue. Monitoring the utilization of the raised funds and the subsequent impact of share dilution will be important.